Navigation Links
Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment
Date:6/14/2011

NEW BRUNSWICK, N.J., June 14, 2011 /PRNewswire-USNewswire/ -- Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals.  For some, it is just a nuisance. For others, it is disabling.

On a continuing quest to find more effective treatment for psoriasis sufferers, an article published in the Journal of Investigative Dermatology reported that the latest data from experiments performed by Actinobac Biomed, Inc., with financial backing from Foundation Venture Capital Group, LLC, successfully demonstrated the in vivo efficacy of the company's drug candidate, Leukothera™, in treating psoriasis in a humanized mouse xenograft transplantation model.  (http://www.nature.com/jid/journal/vaop/ncurrent/abs/jid2011161a.html)

"Our results clearly show that the idea of depleting diseased white blood cells with Leukothera™ is a highly effective strategy for the treatment of psoriasis and other inflammatory diseases," said Dr. Scott Kachlany, Actinobac's founder.

The studies performed at Aarhus University Hospital in Denmark showed Leukothera™ to be as effective as or better than Genentech's once marketed agent, efalizumab (Raptiva®), even when using significantly lower drug dosage levels.  Leukothera™ is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.  

"We provided early seed funding to Actinobac because we are convinced that they are working on breakthrough research that will make a huge impact to thousands and thousands of people around the world suffering from a variety of ailments," said James M. Golubieski, president of Foundation Venture Capital Group (www.foundationventure.com), an affiliate of N
'/>"/>

SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Prototype demonstrates success of advanced new energy technology
2. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
3. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
4. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
5. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
6. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
7. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
8. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
9. Capasso lab demonstrates highly unidirectional whispering gallery microlasers
10. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
11. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- Findings presented at the European Organization ... of NeuroOncology (EANO) and European Society for Medical Oncology ... that EDO-S101 is effective in models of human glioblastoma ... radiotherapy (RT). [ 1 ] ... that combines the DNA damaging effect of bendamustine with ...
(Date:6/3/2015)... CIRTEC Medical Systems , a ... complex Class III implantable devices and minimally invasive devices, ... initiative aimed at identifying potentially marketable biomedical technologies developed ... moving them more efficiently from the laboratory bench to ... working with the world's largest OEMs and most innovative ...
(Date:6/3/2015)... , June 3, 2015  HireLifeScience.com, the premier ... will host its 6 th annual career ... at Raritan Center in Edison, NJ ... include Novo Nordisk, Covance, Actavis and AstraZeneca.  Additional ... be exhibiting are Johnson & Johnson, MedImmune, DSM ...
(Date:6/3/2015)... 03, 2015 Photo-Eyewear™ ( http://www.PhotoEyewear.com ... to PogoTec™, Inc. ( http://www.PogoTec.com ) to better ... device products and technologies it is developing and plans ... business divisions, PogoTec™ will provide focused resources to drive ... , , On-Track™ – There are ...
Breaking Biology Technology:Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 2Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 3Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 4CIRTEC Medical Systems to support new UT Dallas-led Initiative to deliver biomedical technologies from laboratory bench to bedside more efficiently 2AstraZeneca Added as Sponsor for Industry Leading Life Science Hiring Event 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3
... Purpose , Researchers and ... currently employ immuno- or colourimetric assays. These assays suffer from a number of limitations: , ... They are not as commonly available for novel sample matrices such ... They can be relatively costly due to the high volume of ...
... of liquid chromatography/ mass spectrometry and information dependent data acquisition function ... to quantifying their parents during metabolic stability studies. This was once ... Abstract , ... triple quadrupole ion path and is capable of doing conventional multiple ...
... very straightforward method for the analysis of the very ... and monocrotophos in water has been developed. Large volume ... RP18 HPLC column with a polar endcapping. The compounds ... mass spectrometer operated in multiple reaction-monitoring mode. The detection ...
Cached Biology Technology:Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 2Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 3Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 4Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 2Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 3Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 4Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 5Determination of Polar Organophosphorus Pesticides in Aqueous Samples by Direct Injection Using HPLC/MS/MS 2
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... 2013 The following statement is being issued by Robbins Geller Rudman ... Biosciences Securities Litigation SUPERIOR COURT OF THE STATE ... IN RE PACIFIC BIOSCIENCES OF CALIFORNIA , ... SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION Hon. Marie S. ...
... This news release is available in German . ... the current issue of the " Journal of Clinical Investigation " ... begin to fail with increasing age. As a result, signs of ... Alzheimer,s disease, diabetes, cardiovascular disorders and cancer, increases. "Current efforts to ...
... Developing ways to treat cancer patients with drugs that kill ... one of the topics in the premiere segment of the ... Chemical Society (ACS), the world,s largest scientific society. The videos ... DVD . Titled Prized Science: Peter Stang ...
Cached Biology News:Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4Rapamycin: Limited anti-aging effects 2Rapamycin: Limited anti-aging effects 3American Chemical Society launches 2013 edition of popular Prized Science video series 2
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
SH3 Proteins II Sampler Kit 10g each...
Tumor Suppressor Sampler Kit 10 mu g each...
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: